Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

INTRODUCTION: Classical Hodgkin lymphoma (cHL) is the most common pediatric lymphoma. Approximately 10% of patients develop refractory or recurrent disease. These patients are treated with intensive chemotherapy followed by consolidation with radiotherapy or high-dose chemotherapy and autologous ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Greve, Patrick, Beishuizen, Auke, Hagleitner, Melanie, Loeffen, Jan, Veening, Margreet, Boes, Marianne, Peperzak, Victor, Diez, Claudius, Meyer-Wentrup, Friederike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423930/
https://www.ncbi.nlm.nih.gov/pubmed/37583696
http://dx.doi.org/10.3389/fimmu.2023.1229558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423930/
https://www.ncbi.nlm.nih.gov/pubmed/37583696
http://dx.doi.org/10.3389/fimmu.2023.1229558

Ejemplares similares